Eli Lilly and Company (LLY) stated that the company has potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines. The company reaffirmed its 2022 financial guidance on both a reported and non-GAAP basis.
from RTT - Earnings https://ift.tt/lAFQGty
via IFTTT
No comments:
Post a Comment